Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KemPharm Seeks FDA Dispute Resolution Over Apadaz's Abuse Deterrence

Executive Summary

Sponsor hopes to demonstrate that FDA's process for reviewing extended-release abuse-deterrent opioids may not be appropriate for an immediate-release product. Apadaz would be the first immediate-release opioid with an abuse-deterrent claim if approved.

Advertisement

Related Content

Keeping Track: Biosimilar Submissions Galore (And An Approval), Bayer Gets An Oncology Approval, KemPharm Resubmits Apadaz NDA
Black Box 'Best Case' Hopes On Vaginal Estradiol Dashed For TherapeuticsMD
Pain Therapeutics Confident It Has US Approval Pathway Set For Remoxy ER
US FDA Review Management Challenged After Spate Of Complete Response Letters
Can KemPharm's Apadaz Meet FDA Opioid Abuse Deterrent Standards?
KemPharm's Opioid Apadaz Will Likely Miss Out On Abuse Deterrence Claim
FDA Latest Opioid Dilemma: Can Apadaz Stop Snorting Abuse – And Does That Even Matter?
Dispute Resolution Strategies: FDA Clarifies Which Issues Can Be Appealed
If At First You Don’t Succeed, Try Dispute Resolution
FDA Dispute Resolution Process Invoked About 10 Times Annually

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel